icon-folder.gif   Conference Reports for NATAP  
 
  18th International Workshop on
Clinical Pharmacology of Antiviral Therapy
June 14-17, 2017
Chicago, Ill.C
Back grey_arrow_rt.gif
 
 
 
Lack of clinically significant pharmacokinetic interaction between the 3-DAA combination of AL-335, odalasvir and simeprevir for the treatment of chronic HCV infection and an oral contraceptive containing ethinylestradiol and drospirenone
 
 
  Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy, 14-16 June 2017, Chicago, IL,USA
 
Ouwerkerk-Mahadevan S1, Gamil M1, van Hemelryck S1, Hillewaert V1, van Nimwegen M2, Kakuda T3, Biermer M1 1Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium; 2Janssen Biologics BV, Leiden, Netherlands; 3Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies, South San Francisco, USA
 
Short Duration Treatment with AL-335 and Odalasvir, with or without Simeprevir, in Treatment Naïve Patients with Hepatitis C Infection with or without Cirrhosis - (04/24/17)
 
AL-335, A ONCE-DAILY PANGENOTYPIC NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY OVER 7 DAYS IN TREATMENT-NAïVE GENOTYPE 1-4 PATIENTS - (04/18/16)
 
PAN-GENOTYPIC EVALUATION OF AL-335, A CLINICAL STAGE URIDINE ANALOG INHIBITOR OF HEPATITIS C VIRUS POLYMERASE - (04/18/16)
 
Preclinical Characterization of AL-335, a Potent Uridine Based Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C - (05/05/15)

EASL1

EASL2

EASL3